Delivery Order SPE2DB22D1202-SPE2DB25FVFJ1
- Not listed
- The Defense Logistics Agency awarded a $3,302.77 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector units on April 25, 2025, with completion targeted for April 28, 2025. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and represents a continuation of AmerisourceBergen's pharmaceutical supply role within the federal medical procurement system. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,062.43 to AmerisourceBergen Drug Corp for the supply of XYOSTED 50 mg/0.5 ml auto-injector units. The contract is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, awarded on August 21, 2025, with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $1,358.05 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units. This non-set-aside contract is classified as a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and was awarded on August 27, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $2,935.72 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies, valued at $1,006.78 under a firm fixed-price arrangement. The award, issued on June 30, 2025, with an ultimate completion date of July 1, 2025, represents a non-competitive delivery order. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,464.31 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies. This competitively awarded, firm fixed-price contract was issued on June 4, 2025, with an ultimate completion date of June 5, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order valued at $3,403.64 to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector vials on August 6, 2025, with completion scheduled for August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product, reflecting the company's role in...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $1,268.57 to AmerisourceBergen Drug Corp for XYOSTED 75 MG/0.5 ML auto-injector supplies on August 11, 2025, with completion targeted for August 12, 2025. This firm fixed-price delivery order represents a pediatric/adolescent testosterone replacement therapy product to be performed at the contractor's Conshohocken, Pennsylvania location. The award utilized no set-aside designation, indicating open competitive procurement. This...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFJ1Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply vehicle with the Defense Logistics Agency. This award is issued under AmerisourceBergen's Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement extending through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The XYOSTED delivery order fulfills federal medical procurement needs for testosterone replacement therapy, supporting the Defense Health Agency and other military healthcare systems. AmerisourceBergen's consistent receipt of competitively awarded delivery orders demonstrates its capability to meet stringent federal pharmaceutical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 7/23/25 |